Elevated Serum Ferritin and Insulin Resistance in Libyan Women with Polycystic Ovary Syndrome: A Retrospective Case-Control Study

Eshraq Alsherif; Mohamed Alshahrani; Hend Alqeeyadi; Reem Shomakhy; Maha Alaswad; Noor AL-HodaBen-Issa

doi:10.69667/lmj.2517118

Authors

Eshraq Alsherif Department of Prosthodontics, Faculty of Dentistry, University of Tripoli, Libya https://orcid.org/0009-0001-1926-7923
Mohamed Alshahrani College of Applied Science Technology Al-Awata, Tripoli, Libya https://orcid.org/0009-0007-8579-8320
Hend Alqeeyadi Tripoli Fertility Center, Tripoli, Libya https://orcid.org/0009-0001-6062-1525
Reem Shomakhy Department of Medical Laboratories Sciences, University of Tripoli Alahlia, Janzur, Libya https://orcid.org/0009-0006-8626-0410
Maha Alaswad Department of Medical Laboratories Sciences, University of Tripoli Alahlia, Janzur, Libya https://orcid.org/0000-0002-3284-3390
Noor AL-HodaBen-Issa Department of Medical Laboratories Sciences, University of Tripoli Alahlia, Janzur, Libya https://orcid.org/0009-0002-1855-3482

DOI:

https://doi.org/10.69667/lmj.2517118

Keywords:

Polycystic Ovary Syndrome (PCOS), Insulin Resistance, Serum Ferritin, Metabolic Dysfunction, Libyan Women..

Abstract

Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder associated with metabolic and hormonal disturbances, including insulin resistance (IR) and altered iron metabolism. This retrospective case-control study aimed to evaluate serum ferritin levels and insulin resistance in 196 Libyan women (98 PCOS cases and 98 controls) attending the Tripoli Fertility Center. Anthropometric, biochemical, and hormonal parameters were assessed, including body mass index (BMI), waist circumference (WC), lipid profile, and hormonal levels. Results revealed significantly higher BMI, WC, and IR (HOMA-IR) in the PCOS group compared to controls (p < 0.001). Elevated ferritin levels were also observed in PCOS patients (p = 0.001), with a weak but significant correlation between ferritin and IR (r = 0.104, p = 0.01). The PCOS group exhibited a more atherogenic lipid profile, with lower HDL-cholesterol (p < 0.0001) and higher LDL-cholesterol (p < 0.0001). Hormonal analysis showed elevated luteinizing hormone (LH) and a reduced FSH/LH ratio (p < 0.0001), consistent with PCOS pathophysiology. intricate relationship between metabolic dysfunction, hormonal imbalances, and altered iron metabolism in women with PCOS.

متلازمة تكيس المبايض اضطراب غددي معقد يرتبط باضطرابات أيضية وهرمونية، بما في ذلك مقاومة الأنسولين وتغير أيض الحديد. هدفت هذه الدراسة الاستعادية القائمة على المقارنة بين الحالات إلى تقييم مستويات الفيريتين في المصل ومقاومة الأنسولين لدى 196 امرأة ليبية (98 حالة من متلازمة تكيس المبايض و98 حالة من مجموعة الضبط) راجعت مركز طرابلس للخصوبة. تم تقييم المعايير الأنثروبومترية والكيميائية الحيوية والهرمونية، بما في ذلك مؤشر كتلة الجسم، ومحيط الخصر، ومستوى الدهون، ومستويات الهرمونات. أظهرت النتائج ارتفاعًا ملحوظًا في مؤشر كتلة الجسم، ومحيط الخصر، ومقاومة الأنسولين لدى مجموعة متلازمة تكيس المبايض مقارنةً بمجموعة الضبط (p < 0.001). كما لوحظ ارتفاع في مستويات الفيريتين لدى مريضات متلازمة تكيس المبايض (p = 0.001)، مع وجود ارتباط ضعيف ولكنه مهم بين الفيريتين ومقاومة الأنسولين r = 0.104 ، p = 0.01 أظهرت مجموعة متلازمة تكيس المبايض مستوى دهنيًا أكثر تصلبًا، مع انخفاض في كوليسترول البروتين الدهني عالي الكثافة (قيمة P < 0.0001) وارتفاع في كوليسترول البروتين الدهني منخفض الكثافة (قيمة P < 0.0001). أظهر التحليل الهرموني ارتفاعًا في هرمون الملوتن وانخفاضًا في نسبة FSH/LH قيمة P < 0.0001 ، وهو ما يتوافق مع الفسيولوجيا المرضية لمتلازمة تكيس المبايض. هناك علاقة وثيقة بين الخلل الأيضي، والاختلالات الهرمونية، وتغير استقلاب الحديد لدى النساء المصابات بمتلازمة تكيس المبايض

References

Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.

Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800.

Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: Pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019;3(8):1545-1573.

Begum N, Sultana N, Akhter QS, Begum S, Ferdousi S. Serum ferritin as a marker of insulin resistance in polycystic ovary syndrome: A meta-analysis. J Clin Endocrinol Metab. 2021;106(12):e4871-e4882.

Luque-Ramírez M, Álvarez-Blasco F, Botella-Carretero JI, Sanchón R, San Millán JL, Escobar-Morreale HF. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism. J Clin Endocrinol Metab. 2009;94(1):26-32.

Kowalska K, Milaszewska P, Nikołajuk A, et al. Iron metabolism in polycystic ovary syndrome: A systematic review and meta-analysis. Nutrients. 2018;10(11):1664.

Fernández-Real JM, López-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002;51(8):2348-2354.

González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):336-340.

Li X, He T, Yu K, Lu Q, Alkasir R, Guo Y, et al. Markers of iron status in Chinese women with polycystic ovary syndrome and insulin resistance. Int J Clin Exp Med. 2020;8(7):11330-11335.

Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84(6):1897-1899.

Ben-Issa NA, Abofaed M, Alqeeyadi H, Alshahrani M, Alsherif E. Prevalence and Dietary Management of Polycystic Ovary Syndrome among Libyan Women Attending Tripoli Infertility Center. Alq J Med App Sci. 2024;7(1):74-81.

Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618-637.

Nielsen J, Alfirevic Z. Waist circumference as a measure of central obesity: Practical guidelines. BJOG. 2006;113(10):1117-1124.

Sam S, Dunaif A. Polycystic ovary syndrome: Syndrome XX? Trends Endocrinol Metab. 2003;14(8):365-370.

Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347-363.

Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038-2049.

Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: Experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453-462.

Yao X, Chen X, Wu Y, Liu Y, Zhang X. Pathogenesis of polycystic ovary syndrome: A review. J Endocrinol Invest. 2017;40(11):1137-1149.

Kumar P, Arora S. Hormonal profile in polycystic ovary syndrome: A clinical study. J Obstet Gynaecol India. 2018;68(1):58-63.

Kim CH, Kim HK, Bae SJ, Park JY, Lee KU. Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. Metabolism. 2011;60(3):414-420.

El-Mezughi A, Al-Sharbatti S, Moussa M. Consanguinity and its correlates in the Libyan population. J Biosoc Sci. 2015;47(5):669-681